FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the ...

The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai ...

“For decades, the diabetes world has focused on lowering sugar, not on treating the root cause of the disease nor on stopping its progression” said Dr. Dror Chevion, co-founder and CEO of Concenter ...

The average one-year price target for Zenas BioPharma (NasdaqGS:ZBIO) has been revised to $41.56 / share. This is a decrease ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

Expanded leadership bolsters Sciensus' end-to-end model for commercialisation of orphan and specialty medicinal ...

SpyGlass Pharma Inc. filed for an initial public offering to help fund late-stage trials of its intraocular lens and drug delivery solutions to treat patients with chronic eye conditions such as ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

As of Monday, January 05, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 55.44%, which has investors questioning if ...